Investigating how a protein-recycling complex affects treatment resistance in small cell lung cancer.
Understanding the molecular mechanism of a protein-recycling complex in small cell lung cancer treatment resistance.
This study is looking into why some people with small cell lung cancer stop responding to treatments that initially worked well for them, and it's trying to find new ways to improve those treatments by understanding the underlying causes of this resistance.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University Health Network NIH-funded |
| Lab location | 1 site (Toronto, Canada) |
| Project ID | NIH-10684226 on NIH RePORTER |
What this research studies
This research focuses on understanding why small cell lung cancer (SCLC) patients often experience treatment resistance after initially responding well to therapies. The team is exploring the molecular mechanisms behind this resistance, particularly looking at the role of specific proteins and genetic factors. By using advanced techniques like CRISPR to identify resistance mechanisms, the researchers aim to find new therapeutic targets that could improve treatment outcomes for patients. The ultimate goal is to develop novel therapies that can overcome resistance and enhance the effectiveness of existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer, particularly those who have experienced treatment resistance.
Not a fit: Patients with small cell lung cancer who have not undergone treatment or those with non-small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for small cell lung cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promising results in understanding treatment resistance mechanisms in various cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
Toronto, Canada
- University Health Network — Toronto, Canada (Active)
Researchers
- Principal investigator: Lok, Benjamin H — University Health Network
- Study coordinator: Lok, Benjamin H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.